Nitroimidazole antibiotics

Lupin Announces FDA Approval of Supplemental New Drug Application for SOLOSEC® (secnidazole) for the Treatment of Trichomoniasis

Retrieved on: 
Thursday, July 1, 2021

[1] SOLOSEC was approved in the U.S. in 2017 for the treatment of bacterial vaginosis (BV) in adult women.

Key Points: 
  • [1] SOLOSEC was approved in the U.S. in 2017 for the treatment of bacterial vaginosis (BV) in adult women.
  • The supplemental approval makes SOLOSEC the first and only single-dose oral prescription antimicrobial agent approved for the treatment of both trichomoniasis and BV.
  • Research demonstrates that approximately 70% of women with trichomoniasis are PCR positive for BV,[2]" said Jon Stelzmiller, President Specialty, Lupin Pharmaceuticals, Inc.
  • SOLOSEC(secnidazole) 2 g oral granules is an antimicrobial agent indicatedfor the treatment of BV in adult women and trichomoniasis in adults.

Vaginitis Treatment Drugs Market Players Need to Focus on Reinfection Prevention, Concludes Future Market Insights

Retrieved on: 
Tuesday, July 7, 2020

"The vaginitis treatment drugs market is slated to remain positive, with manufacturers concentrating on introducing non-antibiotic drugs as a long-term treatment solution in the wake of a high infection recurrence rate.

Key Points: 
  • "The vaginitis treatment drugs market is slated to remain positive, with manufacturers concentrating on introducing non-antibiotic drugs as a long-term treatment solution in the wake of a high infection recurrence rate.
  • This has spurred market players to accelerate innovations making it possible to detect asymptomatic cases
    Europe's vaginitis treatment drugs market accounts for a quarter of the global vaginitis treatment drugs market.
  • A higher rate of over the counter medicine availability is providing impetus for further growth
    The vaginitis treatment drugs market is experiencing an influx of novel drugs.
  • The market players are incorporating nitro imidazole, tinidazole and metronidazole compounds in their formulations to manufacture vaginitis drugs.

Vaginitis Treatment Drugs Market Players Need to Focus on Reinfection Prevention, Concludes Future Market Insights

Retrieved on: 
Tuesday, July 7, 2020

"The vaginitis treatment drugs market is slated to remain positive, with manufacturers concentrating on introducing non-antibiotic drugs as a long-term treatment solution in the wake of a high infection recurrence rate.

Key Points: 
  • "The vaginitis treatment drugs market is slated to remain positive, with manufacturers concentrating on introducing non-antibiotic drugs as a long-term treatment solution in the wake of a high infection recurrence rate.
  • This has spurred market players to accelerate innovations making it possible to detect asymptomatic cases
    Europe's vaginitis treatment drugs market accounts for a quarter of the global vaginitis treatment drugs market.
  • A higher rate of over the counter medicine availability is providing impetus for further growth
    The vaginitis treatment drugs market is experiencing an influx of novel drugs.
  • The market players are incorporating nitro imidazole, tinidazole and metronidazole compounds in their formulations to manufacture vaginitis drugs.

Lupin Announces SOLOSEC® (secnidazole) Achievement of Preferred Status on Express Scripts National Preferred Formulary, One of the Largest Commercial Formularies in the U.S.

Retrieved on: 
Wednesday, April 22, 2020

As a preferred medication, Solosec will be available at a lower out-of-pocket cost to the represented Express Scripts plan members compared to BV medications which are non-preferred or excluded.

Key Points: 
  • As a preferred medication, Solosec will be available at a lower out-of-pocket cost to the represented Express Scripts plan members compared to BV medications which are non-preferred or excluded.
  • "We believe our pricing and access strategy prioritizes patients by providing a novel, first-of-its-kind BV treatment at pricing designed to reduce barriers to treatment with Solosec."
  • SOLOSEC (secnidazole) 2g oral granules is a 5-nitroimidazole antimicrobial agent indicated for the treatment of bacterial vaginosis (BV) in adult women.
  • SOLOSEC is contraindicated in patients with a history of hypersensitivity to secnidazole, other ingredients of the formulation, or other nitroimidazole derivatives.